Results 51 to 60 of about 279,790 (190)

CAR-T cell. the long and winding road to solid tumors [PDF]

, 2018
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment ...
A Heczey, AH Long, AM Leen, AP Cogdill, ARW Schröder, B Clémenceau, B Moldt, BD Koster, C Carpenito, C Zhang, CE Brown, CH June, CM Bollard, D Kobelt, DM Frey, DM Pardoll, DM Shayakhmetov, DW Lee, EI Buchbinder, EJ Lipson, EM Allen Van, F Bushman, F Ochi, F You, FS Hodi, G Gross, G Sconocchia, G Sconocchia, GL Beatty, H Karlsson, H Koehler, H Torikai, HC Ertl, HJ Pegram, I Caruana, J Badhiwala, J Ellis, J Wang, JE Bakema, JH Sampson, JL Tanyi, K Kono, K Kono, K Kudo, K Tamada, K Töpfer, KC Feng, L Bracci, L Zhang, LE Kandalaft, LM Rogers, LM Whilding, M Chmielewski, M Hegde, M Koneru, M Palma De, M Sadelain, M Sadelain, MA Ligtenberg, MC Milone, MCI Schalkwyk van, MD Stewart, ME Mikucki, ME Weijtens, MJ Besser, MJ Besser, MJ Butte, MJ Osborn, ML Davila, ML Davila, MM D’Aloia, MV Maus, N Ahmed, N Ahmed, O Walisko, P Kebriaei, PB Hackett, PC Schuberth, R Braster, R Monjezi, RA Morgan, RA Morgan, RJ Brentjens, RP Junghans, S Chabot, S Mohammed, S Nayak, S Sakaguchi, S Su, S Toyokuni, S Wilkie, SA Richman, SC Katz, SL Goff, SL Maude, SR Witting, SV Kulemzin, TR Medler, TR Simpson, V Arumugam, VD Fedorov, VD Sadelain, W Wang, XS Zhong, Z Eshhar, Z Grada, Z Wang   +106 more
core   +2 more sources

Bystander CAR−CD8+ T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody

Journal for ImmunoTherapy of Cancer
Although bispecific antibody (BsAb) treatment is a valuable therapeutic option for post chimeric antigen receptor (CAR)-T cell therapy against relapsed/refractory large B-cell lymphoma, it remains to be clarified why it is still effective after intensive
Toshiki Ochi, Tatsuya Konishi, Jun Yamanouchi, Takatsugu Honda, Katsuto Takenaka, Junichi Kato, Masaki Maruta, Shogo Nabe, Yuya Masuda, Meika Matsumoto, Natsumi Kawasaki, Yukihiro Miyazaki, Yasukazu Doi, Yasunori Takasuka   +13 more
doaj   +1 more source

Pneumocystis jirovecii pneumonia after CD4+ T‐cell recovery subsequent to CD19‐targeted chimeric antigen receptor T‐cell therapy: A case report and brief review of literature

Cancer Reports, 2023
Background CD19‐targeted chimeric antigen receptor (CAR)‐T cell therapy involves administration of patient‐derived T cells that target B cells, resulting in B‐cell depletion and aplasia.
Kento Kawata, Haruko Shima, Masayoshi Shinjoh, Fumito Yamazaki, Takumi Kurosawa, Mizuki Yaginuma, Hiroshi Takada, Hiroyuki Shimada   +7 more
doaj   +1 more source

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma

Blood Advances
: Multiple myeloma (MM) relapsing after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell treatment remains a therapeutic challenge. Data on re-exposure to CAR T-cell therapy targeting the same antigen are scarce.
Tim Richardson, Udo Holtick, Jan-Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias Karl Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christof Scheid, Philipp Gödel   +12 more
doaj   +1 more source

CAR T-Cell Therapy: Progress and Prospects [PDF]

Human Gene Therapy Methods, 2017
Lentivirus-mediated transduction of autologous T cells with a chimeric antigen receptor (CAR) to confer a desired epitope specificity as a targeted immunotherapy for cancer has been among the first human gene therapy techniques to demonstrate widespread therapeutic efficacy. Other approaches to using gene therapy to enhance antitumor immunity have been
Wilkins, Olivia, Keeler, Allison M, Flotte, Terence R.   +2 more
openaire   +3 more sources

CAR-T treatment for cancer: prospects and challenges

Frontiers in Oncology, 2023
Chimeric antigen receptor (CAR-T) cell therapy has been widely used in hematological malignancies and has achieved remarkable results, but its long-term efficacy in solid tumors is greatly limited by factors such as the tumor microenvironment (TME).
Ran Chen, Lei Chen, Chaoqun Wang, Hua Zhu, Lijuan Gu, Yuntao Li, Xiaoxing Xiong, Gang Chen, Zhihong Jian   +8 more
doaj   +1 more source

Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy

Molecular Oncology
Chimeric antigen receptor (CAR‐T) cell therapy is a newly developed immunotherapy strategy and has achieved satisfactory outcomes in the treatment of hematological malignancies.
Minmin Wang, Linzi Jia, Xiangpeng Dai, Xiaoling Zhang   +3 more
doaj   +1 more source

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells

Scientific Reports, 2022
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is commonly encountered in various clinical trials. Despite the comprehensive studies to
Li Li, Qing Li, Zi-Xun Yan, Ling-Shuang Sheng, Di Fu, Pengpeng Xu, Li Wang, Wei-Li Zhao   +7 more
doaj   +1 more source

Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells [PDF]

, 2016
The success of adoptive T-cell therapies for the treatment of cancer patients depends on transferred T-lymphocytes finding and infiltrating cancerous tissues.
Ager, Elizabeth, Mohammed, Rebar N., Watson, Heulwen Angharad, Wehenkel, Sophie C.   +3 more
core   +2 more sources

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia [PDF]

, 2018
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and ...
Bader, P, Balduzzi, A, Baruchel, A, Bittencourt, H, Boissel, N, Boyer, M, Buechner, J, Davis, KL, De Moerloose, Barbara, Grupp, SA, Hiramatsu, H, June, CH, Krueger, J, Laetsch, TW, Lebwohl, D, Leung, M, Levine, BL, Martin, PL, Maude, SL, Mechinaud, F, Mueller, KT, Myers, GD, Nemecek, ER, Peters, C, Pulsipher, MA, Qayed, M, Rives, S, Schlis, K, Sen, K, Stefanski, HE, Taran, T, Verneris, MR, Wood, P, Yanik, GA, Zhang, Y   +34 more
core   +2 more sources